Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Erlotinib in Second-Line Non-Small Cell Lung Cancer
NCT00550173Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival at 38 months. Started Nov 2007; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00550173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550173.